Research Paper Volume 11, Issue 8 pp 2327—2342

Figure 1. MCC-555 enhanced adipogenic and osteoblastic differentiation. (A) Adipogenic induction. Confluent C3H10T1/2 cells under adipogenic induction were co-treated with either DMSO (DMSO) or with 1 μM (M1) or 5 μM (M5) MCC-555 in the first 3 days. Cells were stained with Oil Red O at the 8^th day. Representative photos are shown. The stains were quantitated, and the signals of the TZD-treated cells were compared to that of the untreated cells (to which a value of 1 was assigned). ^*, P<10^-4, ^**, P<10^-5 versus DMSO control. (B) RT-qPCR analyses. C3H10T1/2 cells were treated with MCC-555 as described in (A). Total RNAs were isolated at the times as indicated, and the kinetic expression of Pparγ2 and Zfp521 mRNAs were shown. ^*, P<0.05, ^**, P<0.0005 versus counterpart DMSO-treated controls. (C) Osteoblastic induction. Confluent C3H10T1/2 cells were subjected to osteoblastic induction with the co-treatment of either DMSO or 5 μM MCC-555 (M5). Cells were stained with Alizarin Red S at the 28^th day. Representative photos are shown. The stains were quantitated, and the signals of the MCC-555-treated cells were compared to that of the DMSO-treated cells (to which a value of 1 was assigned). ^*, P<10^-8 versus DMSO control. (D) RT-qPCR analyses. Cells treated with 5 μM MCC-555 (M5) as described in (C) were harvested 29 days post-induction, and subjected to RT-qPCR analyses for osteocalcin (OC) and osteopontin (OP) mRNAs. Data represent the mean ± S.D. from three experiments.